We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 178

Pharma in brief - blinded expert evidence favoured: Court dismisses PM(NOC) application for ciclesonide
  • Norton Rose Fulbright Canada LLP
  • Canada
  • May 19 2015

Takeda Canada Inc. and Takeda GMBH (Takeda) brought an application under section 6 of the PM(NOC) Regulations for an order prohibiting


Pharma in brief - SCC invited to revisit key patent issues: standard of review of claims construction and the patentability of methods of medical treatment
  • Norton Rose Fulbright Canada LLP
  • Canada
  • May 14 2015

Bayer Inc. (Bayer) distributes a combination oral contraceptive tablet under the brand name YAZ (drospirenone and ethinylestradiol


Pharma in brief Ontario Court of Appeal closes the door on generic manufacturer claim for unjust enrichment under section 8 of the PM(NOC) Regulations
  • Norton Rose Fulbright Canada LLP
  • Canada
  • May 11 2015

On May 5, 2015, the Court of Appeal for Ontario dismissed Apotex’s appeal from the Ontario Divisional Court, which struck out Apotex’s claim for


Pharma in brief - Canada releases proposed amendments to the PM(NOC) Regulations - patents claiming single medicinal ingredients are eligible for listing on the patent register for combination drugs
  • Norton Rose Fulbright Canada LLP
  • Canada
  • May 1 2015

Today, Industry Canada published proposed amendments to the Patented Medicines (Notice of Compliance) Regulations (PM(NOC) Regulations


IP monitor - I went public with my invention can I still get a patent?
  • Norton Rose Fulbright Canada LLP
  • Canada
  • April 24 2015

According to the Canadian Patent Act, to be granted a patent, an invention must not have been "available to the public" before the patent application


Pharma in brief - Generic v. Generic PM(NOC) application dismissed for non-infringement
  • Norton Rose Fulbright Canada LLP
  • Canada
  • April 21 2015

In a recently published Public Judgment and Reasons, Justice Gleason dismissed Teva Canada Innovation and Teva Pharmaceutical


Pharma in brief - no induced infringement: patent struck from application under s. 6(5)(b) of the PM(NOC) Regulations
  • Norton Rose Fulbright Canada LLP
  • Canada
  • April 16 2015

Prothonotary Lafrenière issued an order pursuant to section 6(5)(b) of the PM(NOC) Regulations striking all allegations relating to one of


IP monitor - a healthy development? A review of CIPO’s new “medical method” examination guidelines
  • Norton Rose Fulbright Canada LLP
  • Canada
  • March 31 2015

On March 18, 2015 the Canadian Intellectual Property Office (“CIPO”) issued a Patent Notice: Revised Examination Practice Respecting Medical Uses


Federal Court declares omeprazole formulation patent valid and infringed
  • Norton Rose Fulbright Canada LLP
  • Canada
  • March 25 2015

On March 16, 2015, Justice Barnes of the Federal Court issued his decision in AstraZeneca Canada Inc. et al v. Apotex Inc., 2015 FC 322, declaring


Patents found obvious; subsequent appeal moot
  • Norton Rose Fulbright Canada LLP
  • Canada
  • March 6 2015

Janssen Inc (Janssen) brought two Applications pursuant to section 6 of the Patented Medicines (Notice of Compliance) Regulations for orders